Also known as: PEGylated Mechano Growth Factor, PEG-MGF Peptide, PEGylated IGF-1Ec
Muscle recovery and tissue repair research
Amount
200 mcg
Frequency
2-3 times per week
Duration
4-8 weeks
Route
SCSchedule
2-3 times per week
Timing
On non-training days or post-exercise; timing not firmly established
โ Rotate injection sites
Duration
4-8 weeks
Repeatable
Yes
Diluent: Bacteriostatic water
Storage: Store lyophilized powder at -20C for long-term storage or 2-8C short-term. Reconstituted solution should be stored at 2-8C and used within 2-3 weeks. Do not freeze reconstituted solution. Protect from light. PEG-MGF is significantly more stable than native MGF due to PEG protection.
IGF-1
When: Baseline
Why: Baseline growth factor levels (MGF signals through IGF-1 pathways)
CBC
When: Baseline
Why: General health baseline and platelet count
CMP with liver enzymes
When: Baseline
Why: Liver and kidney function baseline
Fasting glucose and HbA1c
When: Baseline
Why: Growth factors can affect glucose metabolism
IGF-1
When: 4 weeks
Why: Assess growth factor pathway stimulation
Fasting glucose
When: 4 weeks
Why: Monitor for glucose metabolism changes
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
PEG-MGF (PEGylated Mechano Growth Factor) is a chemically modified form of the MGF E-domain peptide in which a polyethylene glycol (PEG) polymer chain is covalently attached to the native 24-amino acid MGF peptide. This modification, known as PEGylation, is a well-established pharmaceutical strategy used to extend the circulating half-life of therapeutic peptides and proteins by shielding them from proteolytic degradation and reducing renal clearance.
The parent compound, MGF (Mechano Growth Factor), is the unique C-terminal E-domain peptide of the human IGF-1Ec splice variant. First characterized by Geoffrey Goldspink's laboratory at University College London, MGF is naturally expressed in response to mechanical stress and tissue damage, where it activates satellite cells and initiates tissue repair. However, native MGF has an extremely short half-life of approximately 5-7 minutes in circulation, which severely limits its practical utility as a research tool or potential therapeutic agent.
PEGylation addresses this limitation by extending the circulating half-life to several hours, transforming MGF from a rapidly cleared local signal into a compound capable of sustained systemic activity. This pharmacokinetic transformation is the defining difference between PEG-MGF and native MGF.
PEG-MGF retains the same core peptide sequence as native MGF (YQPPSTNKNTKSQRRKGSTFEEHK) and is believed to act through the same biological mechanisms. The primary proposed actions include:
The PEG moiety itself is biologically inert and serves purely as a pharmacokinetic modifier. However, the steric bulk of the PEG chain could theoretically alter receptor binding or cellular uptake compared to native MGF, and no studies have definitively confirmed that PEG-MGF and native MGF produce identical biological effects.
PEGylation typically involves covalent attachment of a linear or branched PEG polymer to the peptide through reactive functional groups, most commonly targeting the N-terminal amino group or lysine side-chain amino groups. For MGF, which contains four lysine residues and two arginine residues, the PEGylation site and PEG polymer size can significantly influence the resulting compound's properties.
The molecular weight of PEG-MGF varies depending on the PEG moiety used. A common configuration uses a 2 kDa PEG chain, yielding a total molecular weight of approximately 5 kDa, though other PEG sizes have been explored in research contexts.
PEG-MGF remains a preclinical research compound with no approved therapeutic applications. It has not entered human clinical trials and is not approved by any regulatory agency for human use. Like native MGF, PEG-MGF is prohibited by WADA under S2 (Growth Factors). The compound is available from research chemical suppliers but is not manufactured under pharmaceutical GMP conditions.
The evidence base for PEG-MGF is limited and largely indirect:
Mechano Growth Factor E peptide (MGF-E) activates human muscle progenitor cells and induces an increase in their fusion potential at different ages, published in Mechanisms of Ageing and Development (Kandalla PK et al., 2011; PMID: 21354439):
Demonstrated that MGF-E peptide activates human muscle progenitor cells with age-dependent responsiveness. Foundational study for MGF and PEG-MGF satellite cell activation research.
Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration, published in Endocrinology (Matheny RW Jr et al., 2010; PMID: 20130113):
Comprehensive review of MGF biology including splicing mechanisms and tissue repair roles. Discusses rationale for PEGylation to overcome short half-life limitation.
Mechano-growth factor peptide has no apparent effect on myoblasts or primary muscle stem cells, published in American Journal of Physiology - Endocrinology and Metabolism (Fornaro M et al., 2014; PMID: 24253050):
Contradictory study finding no effect of synthetic MGF peptide on myoblast proliferation. Raises questions applicable to both native MGF and PEG-MGF.
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction, published in Heart Lung and Circulation (Carpenter V et al., 2008; PMID: 17581790):
Demonstrated cardioprotective effects of MGF E-domain peptide in a mouse MI model. Relevant to PEG-MGF as extended half-life could improve cardiac delivery.
Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain, published in Molecular Brain (Tang JJ et al., 2017; PMID: 28683812):
MGF overexpression promotes neurogenesis in aging mice. Relevant to PEG-MGF as sustained exposure could enhance neurogenic effects.
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 50+ community reports
View community protocolsHGH 191AA: Recombinant human growth hormone guide. Covers 191-amino acid somatotropin, GH deficiency treatment, anti-aging research, and dosing.
IGF-1 DES: Truncated high-potency growth factor. Covers reduced IGFBP binding, enhanced bioavailability, muscle growth research, and safety profile.
IGF-1 LR3: Long-acting IGF-1 analog with 2-3x extended half-life. Covers reduced IGFBP binding, tissue growth potency, dosing, and safety data.
CJC-1295 DAC: Long-acting GHRH analog with extended half-life. Covers Drug Affinity Complex mechanism, GH/IGF-1 elevation, dosing, and side effects.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Research overview of IGF-1 variant peptides โ IGF-1 LR3, IGF-1 DES, MGF, and PEG-MGF โ covering mechanisms, the GH-IGF-1 axis, and preclinical evidence.
Peptide stability and degradation science: oxidation, hydrolysis, physical degradation, environmental factors, and shelf life strategies.
Related content you may find interesting